In this study, we demonstrate that type VI adenylyl cyclase (ACVI) is glycosylated in vivo. Treating HEK293 cells expressing ACVI with tunicamycin to block the addition of N-linked oligosaccharide or removing the N-linked oligosaccharide by in vitro peptidyl-N-glycosidase F digestion reduced the molecular mass of ACVI. Furthermore, tunicamycin treatment suppressed the forskolin-stimulated activity of ACVI. Mutation of either one or both potential N-glycosylation sites (Asn 805 and Asn 890 , located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI. Therefore, ACVI was glycosylated at both Asn 805 and Asn 890 . Confocal analysis indicated that glycosylation was not required for the delivery of ACVI to the cell surface. Although no significant alterations in K m values for ATP or sensitivity to divalent cations were detected, the glycosylation-deficient ACVI mutant N805Q/N890Q-ACVI exhibited much lower forskolin-, Mn 2؉ -, and Mg 2؉ -stimulated cyclase activities than did wild-type ACVI. By contrast, the G␣ s -stimulated cyclase activities of wildtype ACVI and N805Q/N890Q-ACVI were indistinguishable. Furthermore, compared with wild-type ACVI, N805Q/N890Q-ACVI was less sensitive to inhibition mediated by dopamine D2 receptors or by protein kinase C. Collectively, glycosylation of ACVI not only affected its catalytic activity in an activator-dependent manner, but also altered its ability to be regulated by a G␣ i proteincoupled receptor or by protein kinase C.
(G␣ i ) only effectively suppresses some of these membranebound AC isozymes (i.e. type I, V, and VI ACs) (7) . The G␣ i protein was reported to interact with the C1 domain of type V AC (3) . The N-terminal domains of ACs are highly variable and were shown to play modulating roles (9, 10) . A recent study by Chen et al. (11) suggests that the two tandem six-transmembrane segments are critical for the targeting and functional assembly of ACs. The regulatory roles of the transmembrane domains and of the six extracellular loops of ACs remain largely uncharacterized.
Members of the AC superfamily are tightly controlled by various signals and therefore contribute significantly to the complexity and fine-tuning of cellular signaling mechanisms (12) . We are particularly interested in type VI AC (ACVI) because we (9, 13) and others (14, 15) have shown that ACVI can be regulated by multiple intracellular signaling molecules including Ca 2ϩ , protein kinase A, and protein kinase C (PKC). Moreover, ACVI exists mostly in neurons and thus might play a critical role in integrating multiple signals in the central nervous system (16) . Protein phosphorylation is a very important regulatory mechanism of ACVI. We previously demonstrated that PKC-mediated phosphorylation suppresses the catalytic activity of ACVI and that the N-terminal domain of ACVI is required for this regulation (9, 13) . Except for protein phosphorylation, the effects of other potential post-translational modifications on the functional properties of ACVI have not been explored. The effect of glycosylation on ACs is of particular interest because alignment of the amino acid sequences of all membrane-bound ACs revealed a striking conservation of the locations of their potential glycosylation sites. As listed in Table I , all potential N-linked glycosylation sites of ACs are located on the predicted extracellular loop 5 and/or loop 6. Indeed, several AC isozymes (including type II, III, and type VIII ACs) were previously shown to be glycosylated (17) (18) (19) . The glycosylation state of type VIII AC affects its catalytic activity without altering its K m values or its calmodulin dependence (18) . For type III AC, only the fully glycosylated (but not the non-glycosylated) enzyme can be phosphorylated by Ca 2ϩ /calmodulin-dependent kinase (19) . In this study, we demonstrate that ACVI is a glycoprotein. In addition, we define the sites (Asn 805 and Asn 890 ) of the N-linked glycosylation of ACVI. The results from this study suggest that the glycosylation state of ACVI significantly affects its catalytic activity in an activatordependent manner and also alters the sensitivity of ACVI to the inhibition induced by a G␣ i -coupled receptor or by PKC.
Site-directed Mutagenesis-Rat ACVI cDNA was kindly provided by Dr. R. Iyengar (20) . The potential N-linked glycosylation sites of rat ACVI were identified using the GCG software program (Genetics Computer Group, Inc., Madison, WI). Site-directed mutagenesis of Asn 805 and Asn 890 of ACVI was carried out using the Altered Sites ® II in vitro mutagenesis system (Promega) following the manufacturer's protocol. Mutations were confirmed by DNA sequencing. Mutant cDNA was cloned into a hygromycin-resistant vector (pCEP4, Invitrogen, San Diego, CA) using standard molecular biology techniques.
Cell Culture and Transfection-HEK293 cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% (v/v) fetal bovine serum (Life Technologies, Inc.) in an incubation chamber supplied with 5% CO 2 and 95% air at 37°C. The CHOP cell line (21) was a generous gift from Dr. J. W. Dennis (Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada). These CHOP cells were derived from the widely utilized Chinese hamster ovary cells, which express the polyoma large T antigen, and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 200 g/ml Geneticin in 10% CO 2 and 90% air. The coding region of wild-type ACVI or the desired ACVI variant was subcloned into pCEP4. Expression of ACVI in transfected cells was driven by the human cytomegalovirus immediate-early gene enhancer-promoter. The expression construct of the dopamine D2 receptor (D2-R) (22) was kindly provided by Dr. J.-C. Chen (Chang-Gung University, Taoyuan, Taiwan). The coding region of the rat adenosine A 2A receptor (A 2A -R) (23) was subcloned into a eukaryotic expression vector (pcDNA3, Invitrogen) driven by the cytomegalovirus promoter. To obtain HEK293 cells overexpressing ACVI, HEK293 cells were transfected with the desired construct using LipofectAMINE TM (Invitrogen) following the manufacturer's protocol. One day post-transfection, the cells were treated with hygromycin at 500 g/ml for 2ϳ3 weeks to select clones that overexpressed the indicated ACVI variant as determined by Western blot analysis. Multiple colonies of HEK293 cells expressing the indicated ACVI were pooled together for further analysis. For transient transfection experiments, CHOP cells were transfected with the desired construct using the DEAE-dextran method (24) or LipofectAMINE 2000 TM (Invitrogen) following the manufacturer's protocol, which gave ϳ40 and 80% transfection efficiencies, respectively. Cells were harvested 48 -72 h post-transfection for analysis.
SDS-Polyacrylamide Gel Electrophoresis and Western
BlottingMembrane fractions were separated on 8% separating gels according to the method of Laemmli (Ref. 25; see Ref. 13) . Following electrophoresis, the gel was transferred to a polyvinylidene difluoride membrane, blocked with 5% skim milk in phosphate-buffered saline (PBS), and then incubated with the desired antiserum at 4°C overnight. The polyclonal antibody AC6D was raised against amino acids 987ϳ1187 (the C2 domain) of ACVI (13) . Typically, a 1:5000 dilution was used for AC6D unless stated otherwise. The membranes were incubated with peroxidase-conjugated donkey anti-rabbit IgG (1:5000 dilution; Amersham Pharmacia Biotech) for 1 h at room temperature and washed three times with PBS, and the immunoreactive bands were stained using a light-emitting nonradioactive method (ECL, Amersham Pharmacia Biotech).
Immunocytochemical Staining-HEK293 cells expressing the indicated ACVI variant were plated onto poly-L-lysine-coated glass slides and cultured in 6-well (35-mm) dishes. For immunofluorescence staining, cells were first fixed with ice-cold acetone. Slides were preincubated with 10% fetal bovine serum in PBS for 10 min at room temperature and then stained with an anti-ACVI antibody (AC6D, 1:5000 dilution) (13) in the presence of 3% normal goat serum at 37°C for 1 h. Cells were washed with 1% Triton X-100 in PBS, incubated with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG at 37°C for 30 min, washed with 1% Triton X-100 in PBS, and mounted in 50% glycerol in PBS. The pattern of ACVI immunostaining was studied with the aid of a laser confocal microscope (MRC-1000, Bio-Rad). Controls for the specificity of immunofluorescence were determined by omission of the primary antibody in the staining process, which resulted in a loss of immunofluorescence staining.
Measurement of cAMP Content-Intracellular cAMP content was determined as described (26, 27) with slight modification. For HEK293 cells expressing wild-type ACVI or an empty vector, cells were washed twice with Locke's solution (150 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl 2 , 5 mM glucose, 1 mM MgCl 2 , and 10 mM HEPES adjusted to pH 7.4) containing 0.5 mM 3-isobutyl-1-methylxanthine and resuspended in the same solution at 1 ϫ 10 5 cells/0.45 ml in each 1.5-ml tube. To assess cAMP accumulation upon stimulation, 50 l of 10-fold concentrated test reagent was added to each tube and gently mixed at room temperature for 10 min. Cells were then washed twice rapidly with ice-cold Locke's solution. We extracted cellular cAMP by adding 0.3 ml of lysis buffer (20 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5 mM 3-isobutyl-1-methylxanthine, and 20 mM Tris adjusted to pH 7.5) to each tube with gentle mixing. The cAMP content was assayed using the 125 I-cAMP assay system (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom). cAMP accumulation resulting from activation of ACVI was determined as the difference between cAMP levels measured in HEK293 cells expressing wild-type ACVI versus an empty vector (pCEP4). For CHOP cells transiently transfected with the indicated cDNAs, cells were seeded ϳ16 h before transfection at 3.9 ϫ 10 4 cells/well in 24-well plates and transfected with the desired construct(s) using the DEAE-dextran method (24) . Cells were harvested for analysis 48 -72 h post-transfection. To perform cAMP assays, cells were washed with Locke's solution containing 0.5 mM 3-isobutyl-1-methylxanthine and incubated in the same solution for 10 min at room temperature in the presence or absence of the indicated reagent(s). We extracted cellular cAMP by adding 0.3 ml of lysis buffer to each well with gentle mixing. The efficiency of transfection was monitored by cotransfection of the cytomegalovirus-␤-galactosidase plasmid as an internal control. ␤-Galactosidase activity was measured as described elsewhere (28) using o-nitrophenyl ␤-D-galactopyranoside as the substrate. cAMP was assayed using the 125 I-cAMP assay system and was normalized to the activity of ␤-galactosidase for transfection efficiency. cAMP accumulation resulting from activation of the indicated ACVI variant was determined as the difference between cAMP levels measured in HEK293 cells expressing the ACVI variant versus an empty vector (pCEP4).
Adenylyl Cyclase Assay-AC activity was assayed as previously described (27) . Briefly, cells were sonicated using a W-380 sonicator (Ultrasonics, Farmingdale, NY) at a setting of 20% output power for a total of 90 s. The homogenate was centrifuged at 50,000 ϫ g for 30 min to collect the P1 membrane fractions. Unless addressed specifically, the AC activity assay was performed at 37°C for 10 min in a 400-l reaction mixture containing 1 mM ATP, 100 mM NaCl, 0.4 units of adenosine deaminase, 50 mM HEPES, 0.5 mM 3-isobutyl-1-methylxanthine, 6 mM MgCl 2 , 1 M GTP, 0.2 mM EGTA, and 20 g of membrane protein.
Reactions were stopped by the addition of 0.6 ml of 10% trichloroacetic acid. The cAMP formed was isolated by Dowex chromatography (Sigma) and assayed by radioimmunoassay. The enzyme activity was linear for up to 30 min with membrane proteins up to 40 g. The ACVI activity was determined as the difference between the cyclase activities measured in the membrane fractions collected from HEK293 cells transfected with the indicated ACVI cDNA versus an empty vector (pCEP4). For HEK293 cells expressing wild-type ACVI, endogenous cyclase activities represented ϳ30% of the total activity. The estimated concentration of Mg 2ϩ was determined by subtraction of the ATP and EDTA concentrations from the total added MgCl 2 concentration as described by Pieroni et al. (30) .
Recombinant G␣ s Protein Expression-The expression construct pQE60/H6-G␣ s of the G␣ s protein was a generous gift from Dr. W.-J. Tang (University of Chicago, Chicago, IL). The hexahistidine-tagged G␣ s protein was expressed in Escherichia coli and purified using His⅐Bind ® metal chelation resin (Novagen, Madison, WI) as described (2) . To stimulate AC activity, the indicated concentration of G␣ s protein was activated by GTP␥S (20 M) in a 100-l reaction mixture containing 10 mM MgCl 2 , 20 mM Tris, 1 mM EDTA, and 1 mM dithiothreitol for 20 min at 20°C.
Immunoprecipitation and in Vitro Phosphorylation-To carry out the protein phosphorylation study, membrane fractions collected from CHOP cells transiently transfected with the indicated ACVI variant using LipofectAMINE 2000 TM were purified by immunoprecipitation using AC6D as previously described (13) . Immunocomplexes were purified using Sephadex-conjugated protein A (Sigma) and then washed three times with ice-cold radioimmune precipitation assay buffer (50 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8). Phosphorylation by PKC was carried out in a final volume of a 0.1-ml reaction mixture containing 10 mM MgCl 2 , 1 mM CaCl 2 , 0.25% bovine serum albumin, 10 M H-89, 50 M ATP, 50 Ci [␥-32 P]ATP (6000 Ci/mmol, 1 Ci ϭ 37 GBq; Amersham Pharmacia Biotech), 0.1 mM leupeptin, 40 M phenylmethylsulfonyl fluoride, 30 nM okadaic acid, 0.2 mM sodium vanadate, and 20 mM Tris, pH 7.5. The phosphorylation reaction was initiated by the addition of PKC (35 milliunits; Calbiochem) purified from rat brain for 60 min at 30°C and terminated by three washes with ice-cold radioimmune precipitation assay buffer and the addition of 2ϫ SDS sample treatment buffer. Samples were then boiled for 5 min, analyzed by 8% SDS-polyacrylamide gel electrophoresis, and autoradiographed.
RESULTS
Based on computer analysis of the amino acid sequence of rat ACVI (20) , there are two potential glycosylation sites (Asn 805 and Asn 890 ) (Fig. 1 ) that lie within the predicted extracellular loops 5 and 6 of ACVI. These sites are accessible to N-linked glycosylation enzymes in the endoplasmic reticulum lumen. Five other predicted glycosylation sites are unlikely to be functional because they are located in the cytosolic N (Asn 160 ), C1a (Asn 389 ), and C2 (Asn 999 , Asn 1056 , and Asn 1124 ) domains of ACVI. To determine whether ACVI is indeed glycosylated in vivo, HEK293 cells expressing ACVI were treated with tunicamycin to block N-linked glycosylation (31) . Typically, an ACVIspecific immunoreactive band (128 kDa) was observed. Using tunicamycin (5 g/ml) to block glycosylation, the size of this ACVI-immunoreactive band was significantly reduced to ϳ119 kDa ( Fig. 2A) , suggesting that the higher electrophoretic mobility of ACVI might be due to deglycosylation. To verify this hypothesis, membranes expressing ACVI were deglycosylated with N-glycosidase F (Endo-F), which releases N-linked oligosaccharides by cleaving the bond between asparagine and N-acetyl-D-glucosamine. Deglycosylation of ACVI was carried out in the presence of different concentrations of Triton X-100 to ensure proper unfolding of ACVI so that all glycosylation sites were accessible to Endo-F (32) . As demonstrated in Fig.  2B , incubation of ACVI with Endo-F in the presence of 0.1% Triton X-100 increased the electrophoretic mobility of ACVI. These data suggest that ACVI expressed in HEK293 cells appears to be N-linked glycosylated. Interestingly, tunicamycin treatment reduced the forskolin-induced ACVI activity determined by cAMP accumulation (Fig. 2C) , implying that glycosylation of ACVI might play an important role in the functional properties of ACVI. Since tunicamycin abolishes glycosylation in all glycoproteins, caution should be taken in interpreting the effect of glycosylation using tunicamycin. The effect of Endo-F on ACVI activity was not examined because ACVI activities could no longer be detected after only a 1-h incubation in the buffer for Endo-F treatment (0.1% Triton X-100) in the absence of Endo-F (data not shown). This inactivation of ACVI was not due to protein degradation because intact ACVI proteins were observed via Western blot analysis under this experimental condition (data not shown). We therefore did not proceed with 
FIG. 2. ACVI is a glycoprotein.
A, HEK293 cells expressing ACVI were cultured in the absence (Ϫ) or presence (ϩ) of tunicamycin (TM; 5 g/ml) for 2 days to block the addition of N-linked oligosaccharides. Plasma membrane proteins were then collected, fractionated on a 7.5% SDS-polyacrylamide gel, and transferred to polyvinylidene difluoride membranes for Western blot analysis using an anti-ACVI antibody (AC6D) (12) . B, plasma membrane proteins (100 g) collected from HEK293 cells expressing ACVI were deglycosylated using Endo-F at 37°C in the presence of the indicated concentrations of Triton X-100 for 1 h. Samples were then subjected to Western blot analysis using AC6D. further purification or enzymatic analysis of Endo-F-treated ACVI.
To further evaluate the role of glycosylation in the functional properties of ACVI, we then mutated either separately or simultaneously the two potential N-linked glycosylation sites (Asn 805 and Asn 890 ) from asparagine to glutamine and expressed wild-type ACVI and the indicated mutant of ACVI in HEK293 cells. On immunoblots of plasma membranes from HEK293 cells expressing the indicated ACVI variant, N805Q-ACVI and N890Q-ACVI exhibited lower molecular masses than did wild-type ACVI (Fig. 3) . In addition, a further reduction in molecular mass was observed for the double mutant (N805Q/ N890Q-ACVI). Thus, both Asn 805 and Asn 890 are functional N-linked glycosylation sites in vivo.
Notably, the expression levels of wild-type ACVI and the three glycosylation-deficient mutants of ACVI in the plasma membrane fractions were similar (Fig. 3) . Confocal analysis further showed that the expression patterns of wild-type ACVI and the glycosylation-deficient ACVI mutant N805Q/N890Q-ACVI were indistinguishable (Fig. 4) . HEK293 cells overexpressing wild-type ACVI or N805Q/N890Q-ACVI were stained with an anti-ACVI antibody (AC6D) (13) . ACVI staining was observed at cell margins, indicating that ACVI was targeting plasma membranes. Perinuclear staining and intracellular distribution of both wild-type ACVI and N805Q/N890Q-ACVI were also found, suggesting that ACVI is located in intracellular organelles (e.g. the endoplasmic reticulum and Golgi apparatus) during biosynthesis in transfected cells. No immunoreactive signals were observed in untransfected cells. Thus, N-linked oligosaccharide moieties are apparently not required for proper intracellular transport of ACVI.
The enzymatic properties of wild-type ACVI and the glycosylation-deficient ACVI mutant N805Q/N890Q-ACVI were then assessed. Plasma membranes prepared from HEK293 cells expressing the indicated ACVI were assayed for AC activity. As shown in Table II , the apparent maximal forskolininduced AC activity of N805Q/N890Q-ACVI was significantly lower than that of wild-type ACVI. Consistent with this observation, the Mn 2ϩ -stimulated cyclase activity of N805Q/N890Q-ACVI was markedly lower than that of wild-type ACVI (Fig.  5A) . Mn 2ϩ was shown to stimulate AC by interacting with the metal ion-binding sites in the catalytic core complex (33) . We also examined the dose-dependent effect of Mg 2ϩ on the forskolin-stimulated activity of wild-type ACVI and the glycosylation-deficient ACVI mutant. As shown in Fig. 5B , N805Q/ N890Q-ACVI exhibited much lower activity with Mg 2ϩ in the presence of forskolin than did wild-type ACVI. The activities of wild-type ACVI and N805Q/N890Q-ACVI in the absence of forskolin were too low to assess the dose-dependent effect of Mg 2ϩ accurately (data not shown). For both wild-type ACVI and N805Q/N890Q-ACVI, the stimulatory effect of Mn 2ϩ and Mg 2ϩ (in the presence of forskolin) was saturated at ϳ5 and 9 mM, respectively. In contrast to the much lower cyclase activities of N805Q/N890Q-ACVI induced by forskolin or Mn 2ϩ compared with those of wild-type ACVI, no significant difference in the apparent maximal G␣ s -stimulated AC activity of N805Q/N890Q-ACVI or wild-type ACVI was observed. No detectable difference in EC 50 values for forskolin and G␣ s be- 
TABLE II The glycosylation state of ACVI affects forskolin-stimulated (but not G␣ s -stimulated) AC activity
Plasma membrane fractions collected from HEK293 cells expressing wild-type ACVI (WT) or the glycosylation-deficient ACVI mutant N805Q/ N890Q-ACVI were assayed for AC activity. Values represent the means Ϯ S.E. of four to six independent experiments. The K m of the substrate (ATP) was determined by Lineweaver-Burk analysis in the presence of forskolin (300 M) and MgCl 2 (6 mM). VЈ (the apparent maximal adenylyl cyclase activity evoked by forskolin) and the EC 50 for forskolin stimulation were determined from dose-response curves of forskolin concentrations ranging from 1 to 300 M in the presence of 6 mM MgCl 2 and 1 mM ATP. VЈ (the apparent maximal adenylyl cyclase activity evoked by G␣ s ) and the EC 50 for G␣ s -stimulation were determined from dose-response curves of G␣ s concentrations ranging from 4.8 to 480 nM in the presence of 6 mM MgCl 2 and 1 mM ATP. Basal activities were determined in the presence of 6 mM MgCl 2 and 1 mM ATP. tween wild-type ACVI and the glycosylation-deficient ACVI mutant was found either (Table II) . Furthermore, consistent with the observation that the protein expression levels of wildtype ACVI and N805Q/N890Q-ACVI in the plasma membrane fractions are indistinguishable (Fig. 3) , the basal AC activities of wild-type ACVI and N805Q/N890Q-ACVI were similar (Table II). Collectively, the decreased forskolin-stimulated cyclase activity of N805Q/N890Q-ACVI was unlikely to have been caused by a change in its affinity for ATP, Mg 2ϩ , or forskolin or by a reduction in the number of functional ACVI molecules present in the plasma membrane fractions.
To strengthen the hypothesis that G␣ s -induced AC activities are indistinguishable between wild-type ACVI and glycosylation-deficient ACVI, the cDNA of a G␣ s -coupled A 2A -R (23) was cotransfected with that of the indicated ACVI into CHOP cells, which contain no endogenous A 2A -R (data not shown). As demonstrated in Fig. 6 , the activities of wild-type ACVI and the glycosylation-deficient ACVI mutant as determined by cAMP accumulation upon A 2A -R stimulation were similar, whereas the forskolin-stimulated activity of N805Q/N890Q-ACVI was lower than that of wild-type ACVI. These results suggest that the ability of G␣ s to activate ACVI is not affected by the glycosylation state of ACVI. Previous studies demonstrated that ACVI could be effectively suppressed by activated G␣ i (7) . We next determined whether the glycosylation state of ACVI is important for the suppression of ACVI by G␣ i -coupled receptors. CHOP cells were transfected with either wild-type ACVI or N805Q/N890Q-ACVI along with a G␣ i -coupled receptor (D2-R) (22, 34) . AC assays were performed in the presence of forskolin (100 M) at the indicated concentration of a D2-Rselective agonist (Quin). As shown in Fig. 7 , inhibition of wildtype ACVI by D2-R stimulation was more significant than that of the glycosylation-deficient ACVI mutant. The maximal inhibition and the IC 50 value of Quin were determined from doseresponse curves of Quin concentrations ranging from 1 to 300 nM as shown in Fig. 7 . Statistical analysis revealed that the maximal inhibition of wild-type ACVI and N805Q/N890Q-ACVI by Quin statistically differed (64.1 Ϯ 4.9 and 46.1 Ϯ 2.7%, respectively; mean Ϯ S.E. of four independent experiments; p Ͻ 0.05, Student's t test). The IC 50 value of Quin for glycosylation-deficient ACVI (7.7 Ϯ 3.0 nM; mean Ϯ S.E. of four independent experiments) was more than twice that for wild-type ACVI (3.1 Ϯ 0.6 nM; mean Ϯ S.E. of four independent experiments). However, this difference in IC 50 of Quin between these two ACVI variants was not statistically significant (p ϭ 0.179, Student's t test). We previously showed that one of the important regulatory modes for ACVI is PKC-mediated phosphorylation and inhibition (9, 13) . To investigate whether the glycosylation state of ACVI affects its susceptibility to PKCmediated inhibition, we examined whether the addition of purified PKC suppresses the activity of wild-type ACVI and N805Q/N890Q-ACVI. As shown in Fig. 8, PKC determinants from two to four independent experiments). AC activity was measured in the absence of both GTP and MgCl 2 . The difference between the Mn 2ϩ -stimulated cyclase activities of wild-type ACVI and N805Q/N890Q-ACVI is statistically significant (p Ͻ 0.05, two-way analysis of variance followed by the Student-Newman-Keuls method). B, plasma membrane fractions collected from HEK293 cells expressing wild-type ACVI or N805Q/N890Q-ACVI were assayed for forskolin (300 M)-induced cyclase activity in the presence of the indicated concentrations of Mg 2ϩ . Values represent the means Ϯ S.E. The results are from one representative experiment of four independent experiments performed. The difference between the forskolin-stimulated cyclase activities of wild-type ACVI and N805Q/N890Q-ACVI is statistically significant (p Ͻ 0.05, two-way analysis of variance followed by the Student-Newman-Keuls method). respectively. In contrast, PKC treatment exerted no statistically significant effect on the forskolin-induced AC activity of glycosylation-deficient ACVI. Similar to what was observed in HEK293 cells, the expression levels of wild-type ACVI and N805Q/N890Q-ACVI in the plasma membrane fractions of the transfected CHOP cells were similar (Fig. 9A) . Interestingly, PKC effectively phosphorylated both wild-type ACVI and N805Q/N890Q-ACVI to a comparable extent (Fig. 9B) . The lack of an inhibitory effect of PKC on the catalytic activity of N805Q/ N890Q-ACVI is therefore due to the insensitivity of the glycosylation-deficient ACVI mutant to PKC-mediated phosphorylation, but does not result from its not being phosphorylated.
DISCUSSION
The data in this study reveal a specialized role for glycosylation in the functional properties of ACVI. Tunicamycin treatment and endoglycosidase F digestion of ACVI demonstrated that ACVI is a glycoprotein in vivo. Mutational analysis further identified that both Asn 805 and Asn 890 are involved in the glycosylation of ACVI. Although glycosylation is not required for proper targeting of ACVI to the plasma membrane, this post-translational modification of ACVI affects its catalytic activity in an activator-dependent manner and alters its ability to be regulated by a G␣ i protein-coupled receptor or by PKC.
The oligosaccharide moieties of a protein can affect its conformation, stability, and/or transport in cells (36, 37) . For all membrane-bound ACs, potential N-linked glycosylation sites are located on the predicted extracellular loop 5 and/or loop 6 ( Table I ). Note that the amino acid sequences on extracellular loops 5 and 6 vary among AC isozymes. The conserved location of oligosaccharide moieties on these two extracellular loops therefore suggests a conserved structural and/or functional role for glycosylation of ACs. Since both glycosylation sites of ACVI are located on the predicted extracellular loops, which are on the other side of the plasma membrane from the intracellular catalytic core complex (5), it is unlikely that mutations of Asn 805 and Asn 890 per se result in alterations in the enzymatic properties of ACVI observed in this study. Our finding that tunicamycin treatment suppressed forskolin-induced activation of ACVI (Fig. 2C ) also serves as supportive evidence for our hypothesis that glycosylation contributes to the functional properties of ACVI. Glycosylation thus might have more than simply a local effect on ACVI and probably causes a critical change in the tertiary structure of the intracellular catalytic core complex. As reported by Rudd et al. (38) , glycosylation can significantly affect both the local protein surface properties and the overall tertiary structure.
Our finding that the glycosylation state of ACVI affects its catalytic activity activated by forskolin (Table II) is similar to what has been reported for type VIII AC (18) . Glycosylation of ACVI might exert a significant impact on the catalytic core complex when it is directly stimulated by forskolin or Mn 2ϩ (Table II and Fig. 5) . Surprisingly, no significant difference in the apparent maximal G␣ s -stimulated AC activities of N805Q/ N890Q-ACVI and wild-type ACVI was observed (Table II) . In addition, the activities of wild-type ACVI and the glycosylationdeficient ACVI mutant activated by a G␣ s -coupled receptor were similar (Fig. 6) . Glycosylation thus appears to alter the catalytic activity of ACVI in an activator-dependent manner. Among the four ACVI cDNA clones identified from three different species (14, 20, 39, 40) , these two N-linked glycosylation sites (Asn 805 and Asn 890 ) are conserved, further supporting the notion that glycosylation of these two sites is important for the functional properties of ACVI.
The results in this study demonstrate that the glycosylation state of ACVI also plays critical roles in some of the regulatory modes of ACVI. The observation that the glycosylation-deficient ACVI mutant N805Q/N890Q-ACVI was less sensitive to inhibition by G␣ i -coupled D2-R (Fig. 7) implies that glycosylation of ACVI might promote a conformation that allows a more efficient coupling of ACVI to G␣ i proteins. Recent x-ray diffraction analysis and biochemical studies suggest that the interaction site of an AC for G␣ i is located in the C1 domain, whereas that for G␣ s is in the C2 domain (3, 5) . The effect of glycosylation on the ability of a protein to interact with another molecule has been well established. For example, the glycosylation state of the ␦-subunit of the acetylcholine receptor was found to significantly affect its ability to associate with other subunits for receptor assembly (41) . Moreover, the glycosylation-deficient ACVI mutant lost its ability to be regulated by PKCmediated phosphorylation, which is partially mediated by the N-terminal domain of ACVI (9) . It is interesting to note that the glycosylation state of type III AC also contributes significantly to its regulation by calmodulin-dependent protein kinase II (19) . However, in contrast to what was found for type III AC, both wild-type and glycosylation-deficient ACVI can be effectively phosphorylated by PKC (Fig. 9) . Collectively, glycosylation of ACVI differentially modulates the functional domains of ACVI.
Glycosylation of ACVI is a potential mechanism whereby cyclase activity can be regulated. Accumulating evidence suggests that glycosylation levels can be regulated by extracellular signals (42) . Alteration of the glycosylation state might be due to changes in the activity of the enzymes responsible for Nlinked glycosylation. Such enzymes (e.g. galactosyltransferase) can be markedly enhanced during proliferation or by stimulation by kinases (43) (44) (45) . In contrast, chronic exposure to alcohol results in decreased activity of Golgi galactosyltransferases and subsequently causes a lower glycosylation of transferrin (46) . The carbohydrate-deficient transferrin induced by chronic alcohol abuse is very similar to that found in patients with carbohydrate-deficient glycoprotein syndrome type 1 (47) . Tissue-specific N-linked glycosylation has also been demonstrated (8, 48) . The data in this study suggest that although nonglycosylated ACVI is functional, its response to endogenous compounds with forskolin-like activities as proposed elsewhere (2) might be very different from that of fully glycosylated ACVI. Most importantly, non-glycosylated ACVI might not respond to inhibition mediated by PKC or by G␣ i -coupled receptors and may subsequently result in a higher cellular cAMP content than in those cells harboring fully glycosylated ACVI.
Although protein glycosylation has been shown to ensure proper intracellular transport (29) , such a function of glycosylation was not found for ACVI. Confocal analysis demonstrated that removal of both glycosylation sites of ACVI did not significantly affect its cellular distribution (Fig. 4) . These data suggest that the N-linked oligosaccharide moieties are not required for proper intracellular transport. This finding is consistent with our observation that both glycosylated wildtype and glycosylation-deficient ACVI proteins could be detected, at similar levels, in plasma membrane fractions by Western blot analysis (Figs. 3, 4, and 9 ). As for ACVI, correct sorting and targeting in the total absence of N-linked oligosaccharide were previously demonstrated for other membrane proteins (e.g. Na ϩ /I Ϫ symporter (35) and dopamine D1 receptor (36) ).
In summary, we provide evidence demonstrating that ACVI is glycosylated in vivo. Moreover, glycosylation is important for the enzymatic and regulatory properties of ACVI. Because all membrane-bound ACs contain potential glycosylation sites on the predicted extracellular loop 5 and/or loop 6 as those in ACVI, glycosylation may be a general mechanism by which a proper conformation of ACs for regulation is maintained. collected from CHOP cells transiently transfected with the indicated DNA using an anti-ACVI antibody (AC6D) (13) . B, ACVI protein was immunologically purified from the indicated membrane fraction (200 g) using AC6D as described under "Experimental Procedures." Purified wild-type or mutant ACVI protein was then incubated with or without PKC (35 milliunits) as indicated for 60 min at 30°C in the presence of [␥-
32 P]ATP. At the end of incubation, samples were boiled for 5 min and analyzed by autoradiography to determine PKC-mediated phosphorylation levels. The closed and open arrows indicate glycosylated and non-glycosylated ACVI proteins, respectively. Results are from one representative experiment out of three independent experiments, which gave similar results.
